Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 4:21 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 339 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Tumor Necrosis Factor Clear all

Conditions: Rheumatoid Arthritis
Interventions: tocilizumab [RoActemra/Actemra], adalimumab, placebo to tocilizumab, placebo to adalimumab, methotrexate, folate; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 96 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 107
States / cities: Huntsville, Alabama • Phoenix, Arizona • Tucson, Arizona + 95 more

Conditions: Gout Attack
Interventions: Etanercept, Triamcinolone Acetonide; Drug
Lead sponsor: Rutgers, The State University of New Jersey; Other
Eligibility: 18 Years to 85 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: New Brunswick, New Jersey

Conditions: Autoimmune Diseases, Systemic Inflammatory Process, Knee Pain Chronic, Osteoarthritis, Rheumatoid Arthritis
Interventions: Fish Oil, Vitamin D, placebo pill; Drug · Dietary Supplement · Other
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 50 Years and older
Enrollment: 25,871 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2025
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Rheumatoid Arthritis
Interventions: Cimzia, Placebo; Drug
Lead sponsor: Michael Schiff, MD; Individual
Eligibility: 18 Years to 75 Years
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 12
States / cities: Huntsville, Alabama • Peoria, Arizona • Phoenix, Arizona + 9 more

Conditions: Rheumatoid Arthritis
Interventions: Abatacept, Non-biologic Disease Modifying Anti-Rheumatic Drug (DMARD), Anti-Tumor Necrosing Factor (TNF) Therapy; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 1,286 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2009
U.S. locations: 114
States / cities: Birmingham, Alabama • Huntsville, Alabama • Paradise Valley, Arizona + 111 more

Conditions: Rheumatoid Arthritis
Interventions: Etanercept, CHS-0214; Drug
Lead sponsor: Coherus Oncology, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 647 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 37
States / cities: Phoenix, Arizona • Jonesboro, Arkansas • Anaheim, California + 32 more

Conditions: Pain
Interventions: Thalidomide, Ibuprofen or Diazepam; Drug
Lead sponsor: National Institute of Nursing Research (NINR); NIH
Eligibility: Male only
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Rheumatoid Arthritis
Interventions: Certolizumab Pegol (CZP), Arthroscopic synovial tissue biopsy; Drug · Procedure
Lead sponsor: Nathan Wei, MD, FACP, FACR:; Other
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Frederick, Maryland

Conditions: Rheumatoid Arthritis
Interventions: M923, Autoinjector; Biological · Device
Lead sponsor: Momenta Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 7
States / cities: Detroit, Michigan • Greensboro, North Carolina • Oklahoma City, Oklahoma + 3 more

Conditions: Heart Diseases
Interventions: Exercise training; Other
Lead sponsor: East Tennessee State University; Other
Eligibility: 18 Years and older
Enrollment: 52 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 1996 – 1998
U.S. locations: 1
States / cities: Johnson City, Tennessee

Conditions: Rheumatoid Arthritis
Interventions: Teriparatide, calcium citrate, Vitamin D, TNF antagonist; Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 45 Years and older
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2016
U.S. locations: 3
States / cities: Boston, Massachusetts • Worcester, Massachusetts

Conditions: Rheumatoid Arthritis, Crohn's Disease
Interventions: calcitriol; Drug
Lead sponsor: Atlanta VA Medical Center; Federal
Eligibility: 18 Years to 50 Years · Male only
Enrollment: 9 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Arthritis, Psoriatic
Interventions: Guselkumab, Placebo; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 453 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 50
States / cities: Mountain Brook, Alabama • Avondale, Arizona • Flagstaff, Arizona + 46 more

Conditions: Arthritis Rheumatoid
Interventions: Tofacitinib; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 7,807 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021
U.S. locations: 1
States / cities: New York, New York

Conditions: Adalimumab
Interventions: ABP 501-HCF, ABP 501-LCF; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 372 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 3
States / cities: Cypress, California • South Miami, Florida • Salt Lake City, Utah

Conditions: Inflammatory Bowel Diseases
Interventions: Baseline blood sample, Baseline intestinal biopsies, Crohn's disease activity index (CDAI), Post treatment blood sample, Post treatment intestinal biopsies, Baseline stool sample, Post treatment stool sample; Diagnostic Test · Other
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 96 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 2
States / cities: Nashville, Tennessee

Conditions: Psoriasis, Inflammation
Interventions: Methotrexate, Ustekinumab, Etanercept, Adalimumab, Acitretin, UVB Excimer Laser, Narrowband UVB; Drug · Other
Lead sponsor: University Hospitals Cleveland Medical Center; Other
Eligibility: 18 Years to 65 Years
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Type 1 Diabetes Mellitus
Interventions: etanercept; Drug
Lead sponsor: Virginia Commonwealth University; Other
Eligibility: 18 Years to 60 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2017
U.S. locations: 1
States / cities: Richmond, Virginia

Conditions: Spondylitis, Ankylosing
Interventions: Anti-Tumor Necrosis Factor; Drug
Lead sponsor: National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS); NIH
Eligibility: 18 Years to 80 Years
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2002
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Rheumatoid Arthritis
Interventions: Non-interventional; Other
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 265 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 7
States / cities: Beverly Hills, California • Gainesville, Georgia • Coeur d'Alene, Idaho + 4 more

Conditions: Type 1 Diabetes Mellitus
Interventions: Islet transplantation, Antithymocyte Globulin, Daclizumab or Basiliximab, Etanercept, Allogenic human purified pancreatic islets; Procedure · Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 68 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2017
U.S. locations: 9
States / cities: San Francisco, California • Miami, Florida • Atlanta, Georgia + 5 more

Conditions: Stroke, Acute, Gait, Hemiplegic
Interventions: MRI, blood draw, Clinical assessments; Diagnostic Test · Other
Lead sponsor: University of Vermont; Other
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Burlington, Vermont

Conditions: Depressive Disorder, Major, Inflammation
Interventions: Infliximab, Placebo; Drug · Other
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 25 Years to 50 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Rheumatoid Arthritis
Interventions: methotrexate, sulfasalazine, hydroxychloroquine, etanercept; Drug
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years and older
Enrollment: 755 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2009
U.S. locations: 1
States / cities: Birmingham, Alabama

Search by objective public record fields.

A Study of RoActemra/Actemra (Tocilizumab) Versus Adalimumab in Combination With Methotrexate (MTX) in Patients With Moderate to Severe Active Rheumatoid Arthritis And an Inadequate Response to Treatment With Only One Tumor Necrosis Factor (TNF)-Inhibitor

Pilot Study Evaluating The Efficacy Of Etanercept In Acute Gout

Vitamin D and Fish Oil for Autoimmune Disease, Inflammation and Knee Pain

Can TNF-Alpha Incomplete Secondary Responders Attain a Safe and Efficacious Response Switching to Cimzia

Study of Abatacept (BMS-188667) in Subjects With Active Rheumatoid Arthritis on Background Non-biologic DMARDS (Disease Modifying Antirheumatic Drugs) Who Have an Inadequate Response to Anti-TNF Therapy

Comparison of CHS-0214 to Enbrel (Etanercept) in Patients With Rheumatoid Arthritis (RA)

Evaluation of a TNF-Alpha Modulator for Clinical and Molecular Indicators of Analgesic Effect

Rheumatoid Arthritis Treatment and Biopsy Study Assessing Certolizumab Pegol (Cimzia)

Usability of an AI for M923 in Subjects With Moderate to Severe RA

Exercise as a Modulator of Immune Risk Factors for Ischemic Heart Disease

Teriparatide for Joint Erosions in Rheumatoid Arthritis: The TERA Trial

Tumor Necrosis Factor Decreases Vitamin D Dependant Calcium Absorption

Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha Agent

Comparative Effectiveness Of Tumor Necrosis Factor Inhibitors And Tofacitinib Use In Earlier Lines Of Therapy And Use As Monotherapy.

A Study Comparing the Pharmacokinetics (PK) of ABP 501 40 mg/0.4 mL (ABP 501-HCF) and ABP 501 40 mg/0.8 ml (ABP 501-LCF) in Healthy Adult Participants

Cytokines and Genes in Therapeutic Response in Crohn's Disease

Comparative Effectiveness of Psoriasis Treatments on Systemic Inflammation

Islet After Kidney Transplant for Type 1 Diabetes

Blocking Tumor Necrosis Factor in Ankylosing Spondylitis

The Value of Orencia in Rapidly Progressing Rheumatoid Arthritis

Efficacy of Islet After Kidney Transplantation

Biomarkers of Independent Walking Post-Stroke

Cognitive Dysfunction and Inflammation in Depression: Experimental Inhibition Via Infliximab

Treatment of Early Aggressive Rheumatoid Arthritis (TEAR)